Abstract: This document provides methods and materials for using low coverage whole genome sequencing techniques to assess genomes. For example, methods and materials for using targeted nucleic acid amplification and/or capture techniques in combination with low coverage whole genome sequencing techniques to obtain high coverage sequencing data for one or more pre-selected regions of a genome are provided.

Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.

Abstract: An apparatus and computerized method of classifying a patient that has been previously diagnosed to have autosomal dominant polycystic kidney disease (ADPKD) includes providing a computing device having an input/output interface, one or more processors and a memory; receiving a total kidney volume (TKV), a patient height, and a patient age for the patient via the input/output interface; determining a height adjusted TKV (HtTKV) based on the total kidney volume and the patient height using the one or more processors; determining an ADPKD classification for the patient based on the height adjusted TKV and the patient age using the one or more processors; and providing the ADPKD classification for the patient via the input/output interface.

Abstract: Nyquist ghost artifacts in echo planar imaging (“EPI”) are mitigated, reduced, or otherwise eliminated by implementing robust Nyquist ghost correction (“NGC”) directly from two reversed readout EPI acquisitions. As one advantage, these techniques do not require explicit reference scanning. A model-based process is used for directly estimating statistically optimal NGC coefficients from multi-channel k-space data.

Abstract: This document provides methods and materials for improving arteriovenous fistula (AVF) maturation and/or maintaining AVF functionality. For example, methods and materials for using one or more senolytic agents to improve AVF maturation, to maintain AVF functionality, and/or to maintain the patency of an AVF are provided. Methods and materials for using one or more senolytic agents to maintain functionality and/or patency of a venous graft (e.g., a venous graft that bypasses an occluded artery) also are provided.

Abstract: Materials and methods related to using short DNA aptamers to treat demyelinating diseases are provided herein.

Abstract: A composition for delivering a biologic to a subject generally includes a particulate substrate and an mRNA encapsulated by the particulate substrate. In some cases, the mRNA may be indirectly attached to the particulate substrate. The mRNA encodes at least one therapeutic polypeptide. The composition may be delivered to a tissue of a subject to provide a therapeutic benefit to the tissue.

Abstract: A purified exosome product includes spherical or spheroid exosomes with a diameter no greater than 250 nm. In some embodiments, the purified exosome product has a moisture content of no more than 10%. The purified exosome product can be reconstituted to prepare an artificial blood product.

Abstract: An apparatus and computerized method for determining a set of principal components in a multivariate medical data corresponding to a group of subjects comprises: providing a computing device comprising an input/output interface, a memory and one or more processors communicably coupled to the input/output interface and the memory; receiving the multivariate medical data via the input/output interface or the memory; identifying a set of variables based on metabolic patterns between the subjects in the multivariate data using the one or more processors; representing the multivariate medical data corresponding to the set of variables in a high dimensional space between the subjects using the one or more processors; determining the set of principal components by reducing the high dimensional space between the subjects to a compact representational space using the one or more processors; and providing the set of principal components via the input/output interfaces.

Abstract: The present application provides, inter alia, a compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, and R6 are as described herein. Methods of making these compounds and methods of using these compound for treating diseases such as cancer are also provided.

Abstract: Systems and methods for processing data acquired using ultrasound elastography, in which shear waves are generated in a subject using continuous vibration of an ultrasound transducer, are provided. The systems and methods described here can effectively remove motion artifacts associated with vibration of the ultrasound transducer, and can also remove the data sampling misalignment caused when a line-by-line imaging mode is used to acquire data, as is done by many conventional ultrasound scanners. Thus, the systems and methods described here provide techniques for transducer motion correction and for aligning motion signals detected by line-by-line scanning ultrasound systems.

Abstract: Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: wherein X is absent, CH2, or C(O); R1 is H, OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino; R2 is H or C1-6 alkyl; R3 is H, C1-6 alkyl, —C(O)(C1-3 alkyl), or —C(O)O(C1-3 alkyl); R4 is C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R5 groups; and R5 is OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino.

Abstract: Methods for modulating the release and content of extracellular vesicles from target cells using electrical stimulation are provided. Compositions comprising extracellular vesicles or extracts of extracellular vesicles and methods of administering the compositions to a subject are also provided.

Abstract: In accordance with some embodiments, systems, methods, and media for estimating a mechanical property based on a transformation of magnetic resonance elastography (MRE) data using a trained artificial neural network are provided. In some embodiments, a system is provided, the system comprising: a hardware processor programmed to: receive displacement data of tissue in vivo; provide the displacement data to a trained ANN that was trained using noisy input datasets as training data, and derivative datasets corresponding to the noisy input datasets to evaluate performance during training, such that the trained ANN provides an output dataset corresponding to an analytical solution to a derivative of a function represented in an unlabeled input dataset thereby transforming the unlabeled input dataset into its derivative; receive, from the trained ANN, an output dataset indicative of a derivative of the displacement data; and estimate stiffness of the tissue based on the derivative.

Abstract: In various aspects, the present disclosure provides methods for applying ablation therapy to a target tissue region within a patient, which methods include: (a) navigating a catheter to a target tissue region within the patient, the catheter including an elongate body having a proximal portion and a distal portion and a balloon structure positioned at the distal portion of the elongate body, which balloon structure may be permeable to a calcium-ion-containing solution that comprises one or more calcium salts; (b) positioning the balloon structure at the target tissue region; (c) delivering energy to the target tissue region; and (d) eluting the calcium-ion-containing solution from the balloon structure before, during, and/or after delivering the energy to the target tissue region. In various other aspects, the present disclosure provides apparatuses that can be used for performing such methods, among others.

Abstract: This document relates to methods and materials for making and using viruses (e.g., measles viruses or adenoviruses) having a reduced susceptibility to antibody neutralization (e.g., antibody neutralization by serum from measles virus vaccines). For example, recombinant morbilliviruses (e.g., recombinant measles viruses) having a modified H gene and a modified F gene, as well as methods of using a recombinant virus are provided.

Abstract: Embodiments herein relate to implantable cancer therapy systems and stimulation leads thereof with low resistance. In an embodiment, an implantable lead for a cancer treatment system is included having a lead body with a proximal end and a distal end and one or more electric field generating electrodes. The electrodes are disposed along a length of the lead body. A plurality of electrical wires are included and disposed within the lead body. The plurality of electrical wires provides an electrical connection between at least one of the electrodes and the proximal end of the lead body. At least two of the plurality of electrical wires are arranged in parallel and connected to the same electrode. Other embodiments are also included herein.

Abstract: The present disclosure generally relates to systems and methods of use for draining cerebrospinal fluid (CSF) from a brain or a spinal canal in a subject, for example, to treat hydrocephalus or other conditions. In some embodiments, the disclosure relates to a device comprising a flow controller positioned within a conduit that allows CSF to flow through the conduit from a first end to a second end. This may allow the CSF to drain, for example, from an intradural space (such as a thecal sac) into, for example, a paraspinal space, paraspinal vein or other venous space, or peritoneal cavity. A variety of methods may be used to hold or anchor the device in place, for example, an expansion apparatus. In some embodiments, the device can be implanted percutaneously at a location along or within a subject's spinal column, thus reducing the need for surgery, general anesthesia, and hospitalizations.

Abstract: This document provides methods and materials related to selected Zika virus polypeptides. For example. vaccine compositions that contain one or more selected Zika virus polypeptides provided herein and that have the ability to increase immune responses against flaviviruses such as Zika viruses within a mammal (e.g., a human) are provided.

Abstract: The present invention provides materials and methods for using electrical stimulation to treat a mammal having a proteinopathy (e.g., neurodegenerative diseases) or at risk of developing a proteinopathy are provided. For example, the present invention provides materials and methods for modulating glymphatic clearance (e.g., enhancing glymphatic clearance) of pathogenic proteins.